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Abstract
Background: While the deregulation of iron homeostasis in breast epithelial cells is acknowledged, iron-related
alterations in stromal inflammatory cells from the tumor microenvironment have not been explored.
Methods: Immunohistochemistry for hepcidin, ferroportin 1 (FPN1), transferrin receptor 1 (TFR1) and ferritin (FT)
was performed in primary breast tissues and axillary lymph nodes in order to dissect the iron-profiles of epithelial
cells, lymphocytes and macrophages. Furthermore, breast carcinoma core biopsies frozen in optimum cutting
temperature (OCT) compound were subjected to imaging flow cytometry to confirm FPN1 expression in the cell
types previously evaluated and determine its cellular localization.
Results: We confirm previous results by showing that breast cancer epithelial cells present an ‘iron-utilization
phenotype’ with an increased expression of hepcidin and TFR1, and decreased expression of FT. On the other hand,
lymphocytes and macrophages infiltrating primary tumors and from metastized lymph nodes display an ‘iron-
donor’ phenotype, with increased expression of FPN1 and FT, concomitant with an activation profile reflected by a
higher expression of TFR1 and hepcidin. A higher percentage of breast carcinomas, compared to control
mastectomy samples, present iron accumulation in stromal inflammatory cells, suggesting that these cells may
constitute an effective tissue iron reservoir. Additionally, not only the deregulated expression of iron-related
proteins in epithelial cells, but also on lymphocytes and macrophages, are associated with clinicopathological
markers of breast cancer poor prognosis, such as negative hormone receptor status and tumor size.
Conclusions: The present results reinforce the importance of analyzing the tumor microenvironment in breast
cancer, extending the contribution of immune cells to local iron homeostasis in the tumor microenvironment
context.
Keywords: Breast cancer, Ferroportin 1, Iron, Stromal inflammatory cells, Tissue microenvironment
Background
Breast cancer ranks as the most frequent neoplasia and
cause of cancer death, in spite of growing advances in
early diagnosis and novel therapy regimens [1]. A change
in this scenario demands a better understanding of the
cellular and molecular processes involved in breast can-
cer development and progression.
As a fundamental element involved in cell metabolism,
division and proliferation, iron has been implicated as an
important player in cancer development [2]. The argu-
ment that iron may promote the development of breast
cancer is supported by animal studies consistently dem-
onstrating that iron-rich diets or iron injected subcuta-
neously favors breast cancer progression at several
stages [3–6]. From the cell biology perspective, it is now
well accepted that the malignant state in breast epithelial
cells is characterized by a deregulation in cellular iron
homeostasis, as revealed by differences in the expression
of several iron-related proteins relating with markers of
poor outcome [7–11]. Particularly, a marked decrease in
the levels of the iron exporter ferroportin 1 is observed
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both in breast cancer tissue and cancer cell lines with a
higher malignancy potential, denoting the relative “iron-
deficient” phenotype compatible with their increased
proliferative status [12, 13]. In spite of the known impact
of genetic and epigenetic changes of breast epithelial
cells in tumor progression, it is acknowledged that these
are not sufficient for the acquisition of a fully malignant
and invasive potential [14–16]. Stromal inflammatory
cells, which are present in the breast tissue even before
malignant transformation, may also induce alterations in
the breast microenvironment that ultimately can drive
tumorigenesis [17, 18]. Pioneering studies by De Sousa
and co-workers have shown that lymphocytes and
macrophages are capable of synthesizing and secreting
ferritin [19, 20]. More recent work by Alkhateeb and co-
workers not only confirmed that breast cancer-
associated macrophages secrete ferritin, particularly in
response to pro-inflammatory cytokines, but also that
extracellular ferritin stimulates the proliferation of breast
cancer cells [21]. Also, Jezequel and co-workers have de-
scribed ferritin light-chain expression in tumor-
associated macrophages with an M2-like phenotype and
validated it as a prognostic biomarker in node-negative
breast cancer patients [22]. Of note, in vitro M2 polar-
ized macrophages present an iron-release prone pheno-
type, with higher transferrin receptor 1 and ferroportin 1
expression than classically activated M1 macrophages,
which is thought to contribute to its iron recycling func-
tion as scavengers of senescent and apoptotic cells and
in tissue remodeling [23, 24]. To our knowledge, the ex-
pression of ferroportin 1 in breast cancer tumor-
associated lymphocytes and macrophages has never been
addressed before.
In the present study we analyzed the iron-profiles of
epithelial cells, lymphocytes and macrophages in normal
human breast and ductal carcinoma samples and
assessed their association with clinicopathological
markers of cancer progression and behavior. With this
approach we reinforce the evidence that favors the con-
tribution of stromal inflammatory cells to breast tumor
microenvironment while highlighting the potential role
of lymphocytes and macrophages in the regulation of
local iron homeostasis.
Methods
Sample characterization
Selected and stored human breast tissue samples re-
ferred for histological analysis at the Pathology Service
at Centro Hospitalar do Porto (between 2004 and 2009),
were re-analyzed. We selected 131 samples correspond-
ing to 58 cases of invasive ductal carcinomas (IDC), 16
cases of ductal carcinomas in situ (DCIS) and 57 sam-
ples without evidence of breast disease obtained from
breast reduction aesthetic surgery, as controls. Axillary
lymph node samples from 14 non-metastized and 12
metastized IDC were randomly selected from the initial
cohort and analyzed. In addition, 6 frozen core biopsy
samples, collected in 2013, from patients with invasive
ductal carcinomas from which written informed consent
was obtained, were selected for imaging flow cytometry
studies. Pathological and clinical features, including
histological diagnosis, estrogen receptor (ER), progester-
one receptor (PR), human epidermal growth factor 2
(HER-2) status and peripheral white blood cell (WBC)
count data were available from the interin pathology
reports. ER, PR and HER-2 status were assessed by
immunohistochemistry, as routinely done in the Path-
ology Service. HER-2 ambiguous results were con-
firmed by FISH.
Tissue microarray construction
Formalin-fixed paraffin-embedded (FFPE) tissue blocks
and hematoxylin and eosin (H&E)-stained slides were
retrieved from the archive and re-evaluated by an expe-
rienced pathologist (CL). Representative areas from nor-
mal breast epithelium, ductal carcinoma in situ and
invasive ductal carcinoma lesions were selected, marked
on the H&E slides and then sampled into the tissue
microarray (TMA) collector blocks. Most selected le-
sions corresponded to “pure” DCIS or IDC lesions, i.e.,
from samples with the corresponding classification.
Whenever possible, non-malignant and DCIS lesions
were also selected from invasive ductal carcinoma cases.
Two tissue cores from human donor liver samples were
also included in each tissue microarray block, as positive
controls. A total of 452 FFPE 2 mm breast tissue cores
were used for the tissue microarray construction from
which 405 were assessable. 2 μm-thick TMA sections
were cut in a microtome and H&E stained. Histologi-
cally, each core was classified by the pathologist without
previous knowledge of the type of donor sample. Cores
with ‘normal’ breast histology retrieved from DCIS or
IDC samples were further classified as ‘normal in DCIS’
and ‘normal in IDC’, respectively. Representative areas
with malignant lesions from DCIS and IDC were clas-
sified as DCIS “pure lesions” or IDC “pure lesions”,
respectively. DCIS cores retrieved from IDC samples,
without signs of invasion, were classified as DCIS in
IDC. The numbers of cores included for each histo-
logical type and type of donor sample are summarized
in Table 1.
Immunohistochemistry
Immunohistochemical staining was performed in 2 μm-
thick TMA sections with the following antibodies: rabbit
polyclonal anti-human hepcidin-25 antibody (dilution
1:500, Abcam, Cambridge, UK [25]), rabbit polyclonal
anti-human ferroportin 1 antibody (FPN—1:500, Novus
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Biologicals Europe, Cambridge, UK [26]), rabbit poly-
clonal anti-human ferritin antibody (FT—1:1000, Sigma-
Aldrich, MO, USA [27]), mouse monoclonal anti-human
CD71 (TFR1 [clone 10 F11]- 1:80, Novocastra, Newcas-
tle, UK [28]), mouse monoclonal anti-human CD68
(clone Kp-1, 1:2000, A. Menarini Diagnostics, CA, USA),
mouse monoclonal anti-human CD163 (clone MRQ-26,
1:100, Cell Marque, CA, USA), mouse monoclonal anti-
human CD80 (37711, 1:100, R&D Systems, MN, USA),
rabbit polyclonal anti-human CD4 (clone H-370, 1:250,
Santa Cruz Biotechnology, TX, USA) and mouse mono-
clonal anti-human CD8 (clone C8/144B, 1:100, Cell
Marque, CA, USA). The sections were deparaffinized
twice in xylene, rehydrated in decreasing concentrations
of ethanol and washed in water. Heat-mediated antigen
target retrieval was done with DakoTarget Retrieval
Solution (Agilent Technologies, Denmark). Immunohis-
tochemistry was performed according to Novolink
Polymer Detection kit procedures (Leica, Biosystems,
Cambridge, UK). Enzyme reactivity was visualized using
3,3′-Diaminobenzidine tetrahydrochloride (DAB, Sigma-
Aldrich, MO, USA) and slides were counterstained with
Mayers hemalum solution (Merck Millipore, Darmstadt,
Germany), dehydrated and mounted with Entellan
(Merck Millipore, Darmstadt, Germany). The reaction
obtained in all samples was observed in a Leica DM LB
microscope. Each antibody optimum dilution was deter-
mined in a tissue positive control. Slides with replace-
ment of the primary antibody with an antibody of the
same immunoglobulin isotype were integrated in each
experiment as negative labeling controls. A section of
liver tissue from a HAMP (hepcidin) KO mouse was also
included as a hepcidin negative control.
Staining criteria
Tissue specimens from normal control, DCIS and IDC
samples were immunostained for hepcidin, ferroportin
(FPN1), transferrin receptor 1 (TFR1) and ferritin (FT)
proteins and their cellular localization examined in
epithelial cells (Hepcidin, n = 323; FPN1, n = 315; TFR1,
n = 308; FT, n = 325), lymphocytes (Hepcidin, n = 175;
FPN1, n = 174; TFR1, n = 177; FT, n = 244) and
macrophages (Hepcidin, n = 173; FPN1, n = 150; TFR1,
n = 178; FT, n = 245). A semi-quantitative evaluation
method was applied as follows: the score obtained by
the percentage of positive cells (0 % = 0 points; 1–
10 % = 1 point:, 11–20 % = 2 points:, 21–35 % = 3
points:, 36–50 % = 4 points: and >50 % = 5 points)
was multiplied by the score obtained by the staining
intensity (no staining = 0 points, weak staining = 1
point, moderate staining = 2 points and strong stain-
ing = 3 points). We are aware that this type of scoring
results in a higher number of area groups. However,
we considered that grouping the area percentages in
groups with higher intervals would also introduce high
variation inside each group. Cores from the same donor
tissue diagnosed with the same histological type were
grouped and their mean score calculated. Lymph node
iron-related proteins immunoexpression assessment was
done in B cell and T cell areas and in macrophages. Scores
ranged from 0 to 3, where 0 was considered absence of
immunoexpression, 1, low expression, 2, moderate expres-
sion, and 3, high expression of the correspondent iron-
related protein.
Perls’ Prussian blue staining
Hemosiderin deposits were detected by the routine tech-
nique of Prussian blue histochemical staining. Briefly,
after deparaffinization and rehydration in the ethanol
series, sections were immersed in a mixture of equal vol-
umes of potassium ferrocyanide solution and hydro-
chloric acid solution, both at 2 %. Counterstaining was
achieved with nuclear fast red (Merck Millipore,
Darmstadt, Germany). The absence or presence of he-
mosiderin deposits was evaluated in epithelial and
stromal inflammatory cells.
Imaging flow cytometry
OCT-embedded frozen samples from 6 core biopsies
were cut in a cryostat and H&E stained for pathological
assessment of malign disease. After thawing, biopsies
were gently removed with a scalpel and allowed to
mechanically disaggregate with the help of forceps. Cells
were resuspended in 2 % BSA (Bovine Serum Albumin,
Merck Millipore, Darmstadt, Germany) in PBS, and set
for staining in a 96-well standard microplate. A
Neubauer counting chamber was used in order to count
and stain 1 × 106 cells in every assay. After centrifugation
at 2000 rpm and resupension in 0.2 % BSA in PBS, cells
were incubated with mouse monoclonal anti-human
cytokeratin FITC ([clone 1B3] IOTest, Beckman Coulter,
Madrid, Spain), mouse monoclonal anti-human CD68
PE-Cy7 ([clone Y1/82A] eBioscience Affymetrix, CA,
USA), mouse monoclonal anti-human CD3 PerCP-Cy5.5
([clone SK7] BD, Madrid, Spain), rabbit polyclonal anti-
human FPN PE (Novus Biologicals Europe, Cambridge,
Table 1 Number of spots included in TMA receiver blocks
Tissue sample Type of core No. of cores in TMA blocks
Control Normal Samples Normal 119
DCIS Normal in DCIS 12
DCIS pure lesion 54
IDC Normal in IDC 61
DCIS in IDC 39
IDC pure lesion 120
Abbreviations: TMA Tissue Microarray, DCIS Ductal Carcinoma In Situ, IDC
Invasive Ductal Carcinoma
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UK), mouse monoclonal anti-human CD20 PE-Cy7
([clone B9E9] IOTest, Beckman Coulter, Madrid, Spain)
and FPN PE (Novus Biologicals Europe, Cambridge, UK)
[staining 2]. Cells were washed with 0.2 % BSA in PBS
and centrifuged at 2000 rpm prior to fixation with Fix-
ation Medium from Fix & Perm Cell Fixation and
Permeabilization Kit (Life Technologies, CA, USA) and
then resuspended in 0.2 % BSA in PBS for analysis.
Single-stained and unstained cells were used as controls.
Data were acquired in an imaging flow cytometer (Image-
Stream®, Amnis, EDM Millipore, Darmstadt, Germany)
using a 488 nm laser. Images and data were acquired
using INSPIRE Software v4.0 (Amnis, EDM Millipore,
Darmstadt, Germany). Brightfield was detected on chan-
nel 1, FITC on channel 2, PE on channel 3, PerCP-Cy5.5
on channel 5 and PE-Cy7 on channel 6. A total of 100 μL
was loaded per sample and 8000 events meeting the cell
classifier were acquired at a 40× magnification (image
pixel 0.5 μm2). Compensation and analysis were
performed in IDEAS v6.0.348 software (Amnis, EDM
Millipore, Darmstadt, Germany). Data was compensated
through a matrix created based on the single-stained cell
controls. A hierarchical gating strategy was created in the
software in order to identify breast epithelial cells, lym-
phocytes and macrophages. Briefly, first focused cells were
selected (gradient root mean square of the brightfield)
followed by gating on single-cells (brightfield area vs as-
pect ratios). T-Lymphocytes were then selected on an
Intensity_CD3 PerCP-Cy5.5 vs Area on Channel 1 plot, B
Lymphocytes on an Intensity_CD20 PE-Cy7 vs Area on
Channel 1 plot, macrophages on an Intensity_CD68 PE-
Cy7 vs Area on Channel 1 plot and finally epithelial cells
on an Intensity_cytokeratin FITC vs Area on Channel 1.
Gated cells were excluded from further analysis before
selecting the next population. FPN1 intensity in the cell
membrane and cytoplasm was measured through the
creation of masks defining the total area of the cell
and then the correspondent cytoplasm by eroding the
cell membrane in channel 1 (cell membrane = total
cell—cytoplasm).
Laser capture microdissection
Six μm-thick sections from the axillary lymph nodes
were cut and placed in PALM® 1.0 polyethylene
naphthalate (PEN) membrane slides (Carl Zeiss MicroI-
maging GmbH, Germany). Before use, slides were
treated with UV irradiation at 320 nm for 30 min as rec-
ommended by the manufacturer. Immediately prior to
microdissection, slides were deparaffinized, rehydrated
and stained with Mayers hemalum solution (Merck
Millipore, Darmstadt, Germany). Lymphocyte and
macrophage exclusive regions in metastized lymph
nodes were selected, cut and catapulted into individual
PALM® adhesive cap microcentrifuge tubes (Carl Zeiss
MicroImaging GmbH, Germany). Microcentrifuge tubes
with the areas of interest were transported on ice and
RNA was extracted immediately.
RNA extraction and real-time PCR
Isolation of total RNA was performed with the Abso-
lutely RNA FFPE kit (Agilent Technologies, California,
USA), according to the manufacturers’ protocol. Briefly,
sections from each archival sample were deparaffinized
and incubated overnight with a lysis buffer containing
proteinase K and submitted to a series of washes-on-
column until elution. Immediately after, 50 ng of RNA
were reversed transcribed with Maxima First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific, MA,
USA) in a total volume of 20 μL, according to the manu-
facturer’s protocol. Evaluation of FPN1 mRNA levels
(Hs00221783_m1) was performed in a Rotor-Gene 6000
instrument (Qiagen, CA, USA) with a TaqMan® Probe-
based gene expression assay (Applied Biosystems, CA,
USA). Reactions were carried out in triplicate and gene
expression levels calculated relative to GUSB mRNA
levels (Hs99999908_m1). Mean relative expression was
calculated based on the formula ΔCt = Ct target gen-
e—Ct endogenous control gene and fold change on 2(ΔCt
breast tumor samples – ΔCt normal breast samples).
Statistical analysis
Sample distributions were compared using Kruskal-
Wallis or Mann-Whitney’s U tests. Pearson’s Chi-Square
was used to evaluate the differences between categorical
variables. The Spearman’s rank correlation coefficient
was used to evaluate the relationship between variables.
In figures, experimental errors are shown as one stand-
ard error of the mean. Data were analyzed in IBM SPSS
Statistics 20.0 software and statistical significance was
accepted at p < 0.05.
Results
Immunolocalization and relative expression of iron-
related proteins in breast tissue
Immunolocalization of hepcidin, FPN1, TFR1 and FT
was assessed in breast tissue samples of normal controls,
DCIS and IDC cases. As seen in the representative im-
ages illustrated in Fig. 1, different staining patterns were
apparent among sample types and, within samples,
among the different cell types. Leukocyte infiltrate was
much more pronounced in carcinoma than in normal
mastectomy samples. Using the semi-quantitative data
(described in Methods) obtained exclusively in repre-
sentative cores of “pure” lesions, we assessed the ex-
pression of hepcidin, FPN1, TFR1 and FT in epithelial
cells, lymphocytes and macrophage in normal and
cancer (DCIS and IDC) breast tissue. The results are
illustrated in Fig. 2.
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Hepcidin
Hepcidin expression was restricted to the cytoplasm
in all cell types detected. Breast cancer epithelial cells
(in DCIS and IDC) presented a significantly higher
expression of hepcidin than in control normal sam-
ples (p < 0.001) (Fig. 2a). The pattern of differential
expression was similar for the stromal inflammatory
cells analyzed. Breast cancer infiltrating lymphocytes
and macrophages also presented significantly higher
expression of hepcidin (p = 0.002 and p < 0.001, re-
spectively) (Fig. 2b,c).
Ferroportin 1
FPN1 expression in breast epithelial cells was mainly
observed in the cytoplasm but, in some cases, also in
the cell membrane. In lymphocytes and macrophages
it could only be detected in the cytoplasm. Regarding
epithelial cells, no significant differences were ob-
served for FPN1 expression between normal samples,
DCIS and IDC (Fig. 2a). However, in breast carcin-
oma samples, lymphocytes and macrophages
expressed significantly higher levels of FPN1 than in
normal samples (p = 0.014 and p < 0.001, respectively)
(Fig. 2b,c), with FPN1 expression in macrophages be-
ing higher in DCIS samples (p < 0.01 when compared
with IDC samples) (Fig. 2b).
Samples with FPN1-expressing T-lymphocytes are
composed by a combination of CD4 and CD8 cells
(Fig. 3). Tissue section staining with CD68 (macro-
phage lineage marker), CD80 (M1-like) and CD163
(M2-like) led to the observation that while in normal
samples the macrophage population comprises a com-
bination of comparable numbers of cells expressing
CD80 and CD163, in breast carcinoma samples this
population is predominantly composed of CD163-
positive cells, and thus associated with an M2
(alternative) macrophage polarization phenotype
(Fig. 4).
Fig. 1 Hepcidin, FPN1, TFR1 and FT expression pattern in breast tissue. Representative images of Hepcidin, FPN1 (Ferroportin 1), TFR1 (Transferrin
Receptor 1) and FT (Ferritin) immunostaining in normal breast, DCIS (ductal carcinoma in situ) and IDC (invasive ductal carcinoma). A section of
human donor liver is also shown as a positive control. Tissue microarrays containing several samples of breast tissue and human donor liver were
constructed, sectioned and subjected to immunohistochemistry, as described in materials and methods (Original magnification × 400). * and † are
representative of epithelial cells and leukocyte infiltrate, respectively
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Transferrin receptor 1
TFR1 expression was predominantly detected in the
cytoplasm of all the cell types analyzed. Nonetheless, in
epithelial cells of some breast carcinoma samples a clear
membranar staining was also observed. TFR1 expres-
sion was significantly higher in epithelial cells, lympho-
cytes and macrophages from breast carcinoma samples
(p < 0.001) in comparison with control normal samples
(Fig. 2). Furthermore, TFR1 immunoexpression in infil-
trating lymphocytes and macrophages was, as expected,
higher in IDC samples (p < 0.01) when compared with
DCIS (Fig. 2b,c).
Ferritin
FT expression was predominantly observed in the cyto-
plasm of epithelial cells, lymphocytes and macrophages.
Fig. 2 Hepcidin/FPN1 and TFR1/FT phenotype dyads in breast tissue. A semi-quantitative method of assessing the immunoexpression in the TMA
sections was applied by multiplying the area and intensity staining scores, as described in materials and methods. The scores ranged from 0 to
15. Graphs show Mean ± SEM. Significant differences are shown for comparison with the precedent group *p < 0.05, **p < 0.01, ***p < 0.001, Mann
Whitney’s U test; a Immunoexpression score for breast epithelial cells in control normal samples, DCIS (ductal carcinomas in situ) and IDC
(invasive ductal carcinomas) for hepcidin (n = 121), FPN1 (Ferroportin 1, n = 113), TFR1 (Transferrin Receptor 1, n = 119) and FT (Ferritin, n = 119);
b Immunoexpression score for macrophages in control normal samples, DCIS (ductal carcinomas in situ) and IDC (invasive ductal carcinomas) for
Hepcidin (n = 75), FPN1 (Ferroportin 1, n = 62), TFR1 (Transferrin Receptor 1, n = 73) and FT (Ferritin, n = 91); c Immunoexpression score for
lymphocytes in control normal samples, DCIS (ductal carcinomas in situ) and IDC (invasive ductal carcinomas) for Hepcidin (n = 77), FPN1
(Ferroportin 1, n = 70), TFR1 (Transferrin Receptor 1, n = 73) and FT (Ferritin, n = 91)
Fig. 3 FPN1-expressing leukocytes are composed by a mixture of CD4 and CD8 T-cells. Sections of normal breast tissue, DCIS (ductal carcinoma
in situ) and IDC (invasive ductal carcinoma) to reveal the presence of CD4 and CD8 T cells, in FPN1-expressing leukocyte infiltrate. For details see
Materials and Methods (Original magnification × 100- upper FPN images, ×400- CD4 and CD8 images)
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Breast cancer epithelial cells presented a significantly
lower expression of FT than normal samples (p < 0.001)
(Fig. 2a). On the other hand, FT expression in breast
cancer infiltrating lymphocytes was significantly higher
than in normal samples (p < 0.001) (Fig. 2c). No signifi-
cant differences were found regarding FT in macro-
phages, given that its expression was consistently high in
all the samples analyzed (Fig. 2b). Nuclear FT staining in
epithelial cells was also noted. FT staining was also
present in tissue stromal fibers of some IDC cases.
In agreement with these results, suggesting an ef-
fective iron ‘reservoir’ in lymphocytes and macro-
phages, hemosiderin detection through Perls staining
demonstrated that a significantly higher proportion of
carcinoma cases, when compared with control normal
samples, present hemosiderin deposits in stromal in-
flammatory (p = 0.002) and epithelial cells (p = 0.033)
(Fig. 5).
Comparative expression of iron-related proteins in pure
DCIS lesions and DCIS in IDC
We demonstrated that the deregulated expression of
iron-related proteins in breast cancer is not restricted to
the tumor cells, but extends to the lymphocytes and
macrophages in the tumor microenvironment. Given the
fact that FPN1 expression in macrophages is particularly
Fig. 4 FPN1-expressing leukocytes in carcinomas are predominantly M2-like. Sections of normal breast tissue, DCIS (ductal carcinoma in situ) and
IDC (invasive ductal carcinoma) to reveal the presence of cells of the macrophage lineage (CD68), and its classical polarization phenotypes, M1-
like (CD80) and M2-like (CD163), in FPN1-expressing leukocyte infiltrate. For details see Materials and Methods (Original magnification × 100- upper
CD68 images, ×400- squared image series)
Fig. 5 Breast cancer tissue presents a higher accumulation of iron than normal breast. a Percentage of normal and breast cancer samples
presenting hemosiderin deposits in epithelial and stromal inflammatory cells; b-c Representative images of Perls’ iron staining of a normal (b) and
DCIS (c) sample, showing pronounced deposition of hemosiderin in stromal inflammatory cells (arrows) and to a lesser extent in ductal epithelial
cells (asterisk) (Original magnification × 200, ×400)
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high in pre-invasive stages (DCIS), we sought to verify if
these iron-related phenotypes were specific of pure
DCIS or if they could also be observed in DCIS lesions
adjacent to invasive ductal carcinomas (DCIS in IDC).
The results are illustrated in Fig. 6.
Epithelial cells from DCIS pure lesions or from DCIS in
IDC did not exhibit significant differences regarding the
expression of the previously assessed iron-related proteins
(Fig. 6a). Major differences were found, however, for
tumor-associated lymphocytes and macrophages. Lym-
phocytes had a significantly higher expression of hepcidin
(p = 0.030) and TFR1 (p = 0.011) in DCIS in IDC (Fig. 6c),
while macrophages from DCIS pure lesions exhibited a
higher expression of FPN1 than DCIS in IDC (p = 0.036)
(Fig. 6b).
Imaging flow cytometry
In order to confirm the expression of FPN1 in epithelial
cells, lymphocytes and macrophages from breast carcin-
oma samples and further explore its cellular distribution
we resourced to imaging flow cytometry to relatively
quantify it and determine its localization. For that pur-
pose, we used OCT-frozen tissue from 6 patients with
invasive ductal carcinomas, and a panel of antibodies to
identify epithelial cells, T and B lymphocytes and macro-
phages (described in Methods). Furthermore, a mask to
identify specifically the cell membrane and cytoplasm
was built in IDEAS v6.0.348 software to evaluate FPN1
expression in each cell compartment. The ratio between
the median FPN1 intensity in the cytoplasm and mem-
brane was calculated as a putative surrogate for the iron
Fig. 6 Hepcidin/FPN1 and TFR1/FT phenotype dyads in ductal carcinoma in situ lesions (DCIS). A semi-quantitative method of assessing the
immunoexpression in the TMA sections was applied by multiplying the area and intensity staining scores, as described in materials and methods.
The scores ranged from 0 to 15. Graphs show Mean ± SEM. Significant differences are shown for comparison with the precedent group *p < 0.05,
**p < 0.01, ***p < 0.001, Mann Whitney’s U test; a Immunoexpression score for breast epithelial cells in DCIS pure lesions and DCIS lesions in IDC
for Hepcidin (n = 35), FPN1 (Ferroportin 1, n = 35), TFR1 (Transferrin Receptor 1, n = 32) and FT (Ferritin, n = 36); b Immunoexpression score for
macrophages in DCIS pure lesions and DCIS lesions in IDC for Hepcidin (n = 28), FPN1 (Ferroportin 1, n = 27), TFR1 (Transferrin Receptor 1, n = 30)
and FT (Ferritin, n = 33); c Immunoexpression score for lymphocytes in DCIS pure lesions and DCIS lesions in IDC for Hepcidin (n = 26), FPN1
(Ferroportin 1, n = 31), TFR1 (Transferrin Receptor 1, n = 30) and FT (Ferritin, n = 33)
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export capacity of the cell. Representative images are
shown in Fig. 7 and the results are summarized in
Table 2. FPN1 expression could be detected by Imaging
Flow Cytometry in epithelial cells, T lymphocytes, B
lymphocytes and macrophages. Macrophages in breast
cancer tissue presented the highest median fluorescence
intensity of the cell types considered, as a confirmation
of the results presented in Fig. 2b. The ratio between the
median FPN1 intensity in the cytoplasm and membrane
allowed us to notice that FPN1 expression was higher in
the cytoplasm of all the cell types considered, when
compared with the membrane.
Lymph nodes
Considering that the expression of iron-related proteins
in lymphocytes and macrophages varied in different
tumor microenvironments, we extended the observation
to metastized and non-metastized lymph nodes from the
original cohort of patients, whose primary tumors had
been previously analyzed. Hepcidin, FPN1, TFR1 and FT
immunoexpression were assessed in 14 non-metastized
and 12 metastized lymph-nodes (Fig. 8) and semi-
quantitatively scored (Table 3).
Hepcidin immunoexpression in lymph nodes was
mostly restricted to macrophages and scarcely observed
in lymphocytes. Metastized lymph nodes, however, pre-
sented a significantly higher immunoexpression of hep-
cidin in lymphocytes (B cell areas: p = 0.005; T cell areas:
p = 0.018), than in non-metastized lymph-nodes.
FPN1 was uniformly expressed in all the cell types.
In lymph nodes with sinus histiocytosis, lymphocytes
and macrophages had a tendency to lower FPN1 ex-
pression. Remarkably, lymphocytes in metastized
lymph nodes expressed 1.80-fold more FPN1 than in
non-metastized ones, particularly in areas adjacent to
the metastasis (p = 0.002). Expression assessment at
the mRNA level confirmed a 1.48-fold increase in
FPN1 expression in leukocyte areas of metastized
lymph nodes, comparing with non-metastized lymph
nodes (p = 0.057).
TFR1 was mostly expressed in macrophages and ger-
minal center cells, particularly in non-metastized lymph
nodes (p = 0.026). TFR1 was seldom expressed in T-cell
areas, with no significant differences observed between
metastized and non-metastized lymph nodes.
While the immunoexpression pattern of FT was simi-
lar to FPN1, a significantly higher expression of FT was
observed for lymphocytes (p < 0.001), noted particularly
near metastasis areas.
Clinicopathological data
The expression of iron-related proteins was finally corre-
lated with clinicobiological markers of breast cancer be-
havior, specifically hormone receptor and HER2 status.
Results of mean FPN1 expression values in epithelial
cells and macrophages in DCIS and IDC lesions are
shown in Table 4 in relation to the ER, PR and HER2
status. FPN1 expression in IDC lesions was significantly
higher in ER negative (p = 0.018) and in HER2 positive
cases (p = 0.001) in epithelial cells, whereas in DCIS le-
sions FPN1 expression was only associated with negative
ER status in macrophages (p = 0.033). No associations
were found between FPN1 expression and PR status. Re-
garding TFR1 expression, a significantly higher expres-
sion was seen in macrophages of negative PR DCIS
cases (n = 15; p = 0.039) and in lymphocytes and macro-
phages of HER2 positive IDC cases (Ly: n = 79; p = 0.028;
M0: n = 79; p = 0.003). A higher expression of FT in
lymphocytes was observed in negative PR DCIS cases (n
= 15; p = 0.029). All other comparisons were not statisti-
cally significant.
We next analyzed the expression of these iron-related
proteins in relation to local and metastatic tumor growth
in invasive tumors (Table 5). Tumor size was positively
correlated with TFR1 expression in all the cell types con-
sidered (EC: p = 0.027; r = 0.226; Ly: p = 0.041; r = 0.235;
M0: p = 0.017; r = 0.274).
Fig. 7 Representative images of the FPN1 analysis by Imaging Flow Cytometry in breast cancer core biopsies. Epithelial cells (EC) are stained by
an anti-cytokeratin (CK) FITC. T lymphocytes (T Ly) were identifiable by CD3 PerCP-Cy5.5, B lymphocytes (B Ly) by CD20 PE-Cy7 and macrophages
(M0) by CD68 PE-Cy7 (Original magnification × 400)
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Lymph node involvement was not associated with the
expression of these iron-related proteins in the primary
tumor tissue. Of notice, the peripheral blood leukocyte
count at the time of diagnosis was also correlated with
the expression of TFR1 and FPN1 in primary tumor’s
lymphocytes (TFR1: p = 0.001; r = 0.355; FPN1: p = 0.017;
r = 0.274) and macrophages (TFR1: p = 0.002; r = 0.367;
FPN1: p = 0.034; r = 0.244).
Discussion
We would like to start this discussion by placing the
present results in the growing interest on the tissue micro-
environment contribution for malignancy [16, 29, 30]. Thus
far, most of this interest has focused on cytokines and im-
mune response to putative tumor antigens [31, 32]. Re-
cently, however, interest has grown in the interaction
of migrating cells to the tissue microenvironment,
Table 2 FPN1 median expression in IDC samples assessed by Imaging Flow Cytometry
Cell type Mean number of cells
on focus ± SEM
Total cell FPN1
PE MFI ± SEM
Cytoplasm FPN1
PE MFI ± SEM
Membrane FPN1
PE MFI ± SEM
Ratio cyt/memb FPN1
PE MFI ± SEM
EC 3935 ± 605 32.23 ± 4.26 46.08 ± 5.98 18.77 ± 2.32 2.47 ± 0.22
T Ly 53 ± 13 11.99 ± 0.63 15.7 ± 1.14 7.22 ± 0.22 2.31 ± 0.20
B LY 11 ± 7 15.09 ± 2.63 18.76 ± 2.04 9.41 ± 0.87 2.03 ± 0.03
M0 154 ± 38 69.82 ± 9.26 105.55 ± 23.82 53.11 ± 7.53 2.00 ± 0.001
Abbreviations: FPN1 Ferroportin 1, IDC Invasive Ductal Carcinoma, MFI Median Fluorescence Intensity, SEM Standard Error of the mean, Cyt Cytoplasm, Memb
Membrane, EC Epithelial Cells, Ly Lymphocytes, M0 Macrophages
Fig. 8 Representative images of Hepcidin, FPN1, TFR1 and FT immunostaining in non-metastized and metastized lymph nodes. Archived lymph
nodes from cases with previously analyzed primary invasive ductal carcinomas were sectioned and subjected to immunohistochemistry, as
described in materials and methods. Boxes indicate lymph node areas near metastasis. Note prominent germinal centers in non-metastized lymph
nodes (×400 original magnification figures are shown below its × 200 correspondent figures). M, metastasis; LN, lymph node
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namely macrophages, neutrophils and certain lympho-
cyte subsets [14, 33, 34].
Cells migrating to a tumor microenvironment must
benefit in general from the tumor associated develop-
ment of new vessels [35]. Angiogenesis is thought to
provide nutritional advantage to the transformed malig-
nant cell. Yet, very few studies have focused on an obvi-
ous nutrient associated with cell division, such as iron.
The present study sought, to a certain extent compen-
sate for that scanty interest.
Thus, we approached the question of the iron homeo-
stasis deregulation in breast cancer by analyzing the spe-
cific iron-related phenotypes of different cell types
present in the tumor tissue namely epithelial cells,
lymphocytes and macrophages, and correlating the iron-
related phenotypes with clinicopathological markers of
disease prognosis. The analysis of iron-related pheno-
types in breast ductal carcinoma epithelial cells con-
firmed previous observations that they display a
phenotype of relative iron deficiency, characterized by a
marked increase in TFR1 expression (for review see
[36]) and downregulation of FT [21]. Although we ob-
served an increase in hepcidin expression in breast can-
cer tissue, as previously described, we were not able to
demonstrate a concomitant decrease in FPN1 expression
in breast cancer epithelial cells, compared with normal
epithelial cells [12, 13, 37]. Although not analyzed in our
study, results from Wang et al. suggest that the ‘iron-de-
ficient’ phenotype of breast cancer cells may be driven
by the increased expression of the iron-regulatory pro-
tein (IRP) 2 [38]. The discrepancy found with previous
reports regarding FPN1 might be due to the inclusion,
in those studies, of different breast cancer types besides
ductal carcinomas or by the assessment of FPN1 at the
transcriptional level instead of the protein level, or still
due to our limited number of samples. Also, we cannot
exclude the influence of other regulatory mechanisms
on FPN1 expression, other than hepcidin-mediated fer-
roportin 1 downregulation at the post-translational
level, such as epigenetic mechanisms, deregulation of
Nrf2 and MZF-1 expression [37] or a HIF-2α
dependent pathway [39].
The analysis of iron-related phenotypes in stromal in-
flammatory cells revealed that infiltrating macrophages
and lymphocytes display an “iron-donor” phenotype with
increased expression of both FPN1 and FT concomitant
with an activation profile reflected by a higher expres-
sion of hepcidin and TFR1. The increased FPN1 expres-
sion was particularly evident in macrophages of DCIS
lesions (see Figs. 2 and 6), but was also clear in
Table 3 Analysis of iron-related proteins expression in the LN of
patients with IDC
Non-metastized LN Metastized LN
Cell type Mean ± SEM Mean ± SEM p
Hepcidin B cell areas 0.08 ± 0.08 0.62 ± 0.14 0.005
T cell areas 0.15 ± 0.10 0.62 ± 0.14 0.018
M0 2.00 ± 0.00 1.92 ± 0.08 ns
FPN1 B cell areas 1.38 ± 0.14 2.23 ± 0.17 0.002
T cell areas 1.38 ± 0.14 2.23 ± 0.17 0.002
M0 1.92 ± 0.08 2.23 ± 1.17 ns
TFR1 B cell areas 1.92 ± 1.18 1.08 ± 0.27 0.026
T cell areas 1.00 ± 0.11 1.08 ± 0.08 ns
M0 2.00 ± 0.11 2.31 ± 0.13 ns
FT B cell areas 1.77 ± 0.12 2.77 ± 0.12 <0.001
T cell areas 1.54 ± 0.14 2.62 ± 0.14 <0.001
M0 3.00 ± 0.00 3.00 ± 0.00 ns
Abbreviations: LN Lymph Node, IDC Invasive Ductal Carcinoma, SEM Standard
Error of the Mean, M0 Macrophages, FPN1 Ferroportin 1, TFR1 Transferrin
Receptor 1, FT Ferritin, NS Not Statistically Significant
Table 4 FPN1 expression in epithelial cells and macrophages in carcinomas according to clinicopathological variables
DCIS (Mean ± SEM) IDC (Mean ± SEM)
Clinicopathological
variable
EC Significance level. M0 Significance level. EC Significance level. M0 Significance level.
ER status n = 22 ns n = 14 p = 0.033 n = 103 p = 0.018 n = 73 ns
ER- 6.29 ± 0.65 13.04 ± 0.87 7.47 ± 0.88 7.17 ± 0.95
ER+ 4.51 ± 0.43 7.75 ± 2.14 5.18 ± 0.31 6.01 ± 0.34
PR status n = 22 ns n = 14 ns n = 103 ns n = 73 ns
PR- 6.01 ± 0.61 11.59 ± 1.64 6.47 ± 0.65 7.25 ± 0.77
PR+ 4.48 ± 0.46 9.30 ± 1.80 5.40 ± 0.36 5.83 ± 0.35
HER2 status n = 22 ns n = 14 ns n = 101 p = 0.001 n = 73 ns
HER2- 5.76 ± 0.63 9.00 ± 2.45 5.21 ± 0.35 6.02 ± 0.38
HER2+ 4.98 ± 0.57 11.76 ± 1.34 7.47 ± 0.64 6.89 ± 0.74
Abbreviations: DCIS Ductal Carcinoma In Situ, IDC Invasive Ductal Carcinoma, ER Estrogen Receptor, PR Progesterone Receptor, HER2 Human Epidermal growth
factor Receptor 2, EC Epithelial Cells, Ly Lymphocytes, M0 Macrophages, FPN1 Ferroportin 1, TFR1 Transferrin Receptor 1, FT Ferritin, ns Not Statistically Significant,
SEM Standard Error of the Mean
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lymphocytes, not only in the primary tumor site but also
in metastized lymph nodes (see Figs. 2c and 8 and
Table 3). The simultaneous overexpression of TFR1 and
FT, and hepcidin and FPN1 in lymphocytes and macro-
phages questions the established principles of iron-
related proteins’ regulation at the post-transcriptional
and –translational levels. Considering the role of IRPs 1
and 2 in a situation of high iron levels, as expected in a
breast cancer setting, IRP binding to 5′- untranslated re-
gion (UTR) of FT and lack of stabilization at the 3′-UTR
of TFR1 would lead to an increased FT translation, with
a concomitant decrease in TFR1. Unexpectedly, this was
not observed, Although TFR1 is classically viewed, in
this context, for its role in iron acquisition and malig-
nant cell nutrition, there is evidence showing an alterna-
tive role for TFR1 in the activation of T cells,
independently of iron-uptake [36, 40, 41]. Furthermore,
we cannot disregard the fact that FT detection was
achieved with a polyclonal antibody, not discriminating
the heavy and light subunits, which could be argued as
not reflecting iron accumulation in these cells. However,
the fact that we also demonstrated that over 40 % of
DCIS and IDC samples present stromal inflammatory
cells with hemosiderin deposits supports our hypothesis
that these cells may constitute an effective iron reservoir
potentially contributing to tumor nutrition. The ob-
served concurrent increased expression of hepcidin and
FPN1 in lymphocytes and macrophages of breast ductal
carcinomas may also argue in favor of such a nutritional
role. Studies from others have also demonstrated a simi-
lar hepcidin-independent mechanism of iron export,
reflecting a role for heme. They showed that heme de-
rived from erythrophagocytosis can stimulate FPN1
transcription in primary cultures of bone marrow de-
rived macrophages and that hepcidin was not able to
block iron-heme export during erythrocyte-iron recyc-
ling by macrophages [42, 43].
Markers of iron deregulation in stromal cells were also
found here significantly associated with other clinico-
pathological markers of poor prognosis, namely hor-
mone receptor status negativity and tumor size (Tables 4
and 5). Several studies had already focused on the estab-
lishment of associations between the immune profile of
the infiltrating leukocytes in the tumor and established
clinicopathological variables of breast cancer outcome
[44–46] but very few have approached the association
with iron-related proteins. Interestingly, Britten et al.
had already demonstrated that spleens from patients
with Hodgink’s disease presented a higher expression of
ferritin in macrophages, particularly around tumor nod-
ules [47]. The present results point to the fact that de-
regulation of iron metabolism occurs not only at the
primary tumor microenvironment, but also in preferen-
tial metastatic niches. To our knowledge, only Jezequel
and coworkers have previously described the expression
of an iron-related protein (ferritin light-chain, FTL) in
stromal cells as a prognostic marker in node-negative
breast cancer patients [22]. In the present study, and for
the first time, an association between the expression of
iron-related proteins in lymphocytes and macrophages
and negative hormone receptor status in DCIS and
tumor size was demonstrated. Moreover, neither the ex-
pression of FPN1 and FT in axillary lymph nodes nor
the association of FPN1 and FT overexpression in lym-
phocytes with the presence of breast cancer metastasis
has been previously described. In summary, these signifi-
cant associations observed for lymphocytes and macro-
phages reinforce a reason for interest in their
contribution for the tumor microenvironment.
This study raises some new questions that deserve to
be analyzed. The first one is how stromal cells acquire
their “iron donor” phenotype. Are they responding lo-
cally to signals derived from cancer cells? Are they mo-
bilized from the peripheral blood with this phenotype?
Further studies should be performed to clarify this ques-
tion. One may consider however that, at the systemic
level, macrophages and lymphocytes constitute import-
ant iron storage compartments involved, respectively, in
the recycling of iron from senescent erythrocytes and in
the uptake of non-transferrin-bound iron [48–50]. Based
on the original hypothesis of de Sousa of the immune
system in the surveillance of the potential iron toxicity
associated with red blood cell circulation and more re-
cently extended by Pinto et al. work in 2014 [49, 51], this
circulating compartment might, indeed, be responsible
for delivering iron locally in situations of increased blood
flow, such as in tumor-derived angiogenesis, and hence
contribute to tumor sustained growth through iron
Table 5 Correlation table between tumor size and TFR1 expression
TFR1 (Mean ± SEM)
Clinicopathological variable EC Corr. Coeff. Sig Ly Corr. Coeff. Sig M0 Corr. Coeff. Sig
Tumor size n = 96 p = 0.027 n = 76 p = 0.041 n = 76 p = 0.017
T1 6.69 ± 0.56 3.37 ± 0.31 5.39 ± 0.47
T2 7.83 ± 0.93 4.99 ± 0.57 6.94 ± 0.63
> T3 9.00 ± 4.83 3.47 ± 0.65 7.00 ± 1.34
Abbreviations: EC Epithelial Cells, Ly Lymphocytes, M0 Macrophages, TFR1 Transferrin Receptor 1, SEM Standard Error of the Mean
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nutrition [52]. This notion is further supported by our
present data showing a highly significant correlation be-
tween the number of circulating leukocytes at the time of
diagnosis and the high expression of FPN1 and TFR1 in
breast cancer infiltrating lymphocytes and macrophages.
Conclusion
In summary, the results presented here confirm that the
deregulation of iron metabolism is an aspect common to
several cellular types of breast cancer tissue, and not re-
stricted to epithelial cells. Moreover, this deregulation of
iron-related proteins in infiltrating lymphocytes and
macrophages add evidence to the view that stromal cell
responses in the breast microenvironment may contrib-
ute critically to tumor progression [53, 54].
With the present cross-sectional approach it was not
possible to establish a real timeline for breast cancer de-
velopment and progression. Moreover, the fact that this is
an anonymous cross-sectional study without access to
follow-up data, has limited the comprehension of the
value of iron-related alterations in infiltrating lymphocytes
and macrophages of the breast tumor microenvironment.
Subsequent prospective studies monitoring the expression
of these iron-related proteins in patients are still needed
to validate the significance of local iron-profiles as relevant
markers of breast disease progression. Furthermore, the
analysis of IRP expression in specific breast tissue cell
types may provide additional insight into the regulation of
iron homeostasis in breast cancer. Future in vitro studies
should be designed in order to confirm not only the cap-
acity of lymphocytes and macrophages to donate iron to
breast epithelial cells but also to explore how malignant
cells could influence their environment in order to acquire
iron beyond stimulating angiogenesis.
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